Legend Biotech (Legend Biotech) Cash-to-Debt : 3.98 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Legend Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Legend Biotech's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.98.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Legend Biotech could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Legend Biotech's Cash-to-Debt or its related term are showing as below:

LEGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.61 Med: 16.65 Max: 149.92
Current: 3.98

During the past 6 years, Legend Biotech's highest Cash to Debt Ratio was 149.92. The lowest was 3.61. And the median was 16.65.

LEGN's Cash-to-Debt is ranked worse than
58.05% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs LEGN: 3.98

Legend Biotech Cash-to-Debt Historical Data

The historical data trend for Legend Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Legend Biotech Cash-to-Debt Chart

Legend Biotech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

26.12

149.92

7.18

3.61

3.98

Legend Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															3.61	2.70	4.75	4.44	3.98

Competitive Comparison of Legend Biotech's Cash-to-Debt

For the Biotechnology subindustry, Legend Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Legend Biotech's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Legend Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Legend Biotech's Cash-to-Debt falls into.

Legend Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Legend Biotech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1308.717	/	(3.175	+	325.497)
	=	3.98

Legend Biotech's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1308.717	/	(3.175	+	325.497)
	=	3.98

Legend Biotech (NAS:LEGN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Legend Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Legend Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Legend Biotech (Legend Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Legend Biotech Corp (NAS:LEGN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

9LB:Germany

Address

2101 Cottontail Lane, Somerset, NJ, USA, 08873

Website

https://www.legendbiotech.com

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America.